» Articles » PMID: 16380613

The Natural History of Primary Progressive MS in British Columbia, Canada

Overview
Journal Neurology
Specialty Neurology
Date 2005 Dec 29
PMID 16380613
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary progressive multiple sclerosis (PPMS) has a distinct clinical phenotype and has historically been understudied with few longitudinal natural history studies spanning a reasonable time period. The authors examined patient characteristics, disease progression, and associated risk factors in the PP population of British Columbia, Canada.

Method: The authors report on the PP population from an upcoming publication of the natural history study of definite MS in British Columbia, Canada. The main outcome was sustained progression to Expanded Disability Status Scale (EDSS) 6, secondary outcome time to EDSS 8. Risk factors for progression included sex, onset age, onset symptoms, and for time to EDSS 8, time to EDSS 6.

Results: Of the 2,837 patients with definite MS in the original study, 352 (12.4%) had PPMS. Mean disease duration was 17.2 years (0.3 to 49.6 years), mean onset age was 40.1 years (SD 11.5), and 53% (187) were female. One-quarter of the population had reached EDSS 6 after 7.3 years from onset, yet another 25% still did not require a cane after 25 years. Sex, onset age, and onset symptoms did not predict progression (p > 0.05). A shorter time to EDSS 6 predicted a shorter time to EDSS 8 (p < 0.0005).

Discussion: Progression of disability was slower than found in previous primary progressive multiple sclerosis natural history studies. However, considerable variation existed, with few predictors, other than "sooner to cane, sooner to wheelchair."

Citing Articles

A data-driven model of disability progression in progressive multiple sclerosis.

Garbarino S, Tur C, Lorenzi M, Pardini M, Piana M, Uccelli A Brain Commun. 2025; 7(1):fcae434.

PMID: 39777254 PMC: 11704797. DOI: 10.1093/braincomms/fcae434.


The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry.

Braune S, Bluemich S, Bruns C, Dirks P, Hoffmann J, Heer Y BMC Neurol. 2023; 23(1):258.

PMID: 37407914 PMC: 10320981. DOI: 10.1186/s12883-023-03273-9.


Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.

Portaccio E, Fonderico M, Iaffaldano P, Pasto L, Razzolini L, Bellinvia A JAMA Neurol. 2022; 79(9):869-878.

PMID: 35877104 PMC: 9315975. DOI: 10.1001/jamaneurol.2022.1929.


Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen.

Bauthman M Cureus. 2022; 14(2):e22120.

PMID: 35186606 PMC: 8844373. DOI: 10.7759/cureus.22120.


Apparent changes in the epidemiology and severity of multiple sclerosis.

Koch-Henriksen N, Magyari M Nat Rev Neurol. 2021; 17(11):676-688.

PMID: 34584250 DOI: 10.1038/s41582-021-00556-y.